Table of Contents

CHAPTER 1. BASICS OF PATENT LAW

I. INTRODUCTION

§ 1:1 In general
§ 1:2 Basic patent process
§ 1:3 Structural organization of a patent

II. PATENT CLAIMS

§ 1:4 Importance of patent claims
§ 1:5 Person of ordinary skill in the art
§ 1:6 Organizational structure of the claim—Preamble
§ 1:7 Transition phrase
§ 1:8 Organizational structure of the claim—Body of the claim
§ 1:9 Common types of pharmaceutical claims—Base chemical/compound claims
§ 1:10 —Salts, esters, and solvates
§ 1:11 —Enantiomers
§ 1:12 —Polymorphs
§ 1:13 —Combinations of APIs
§ 1:14 —Formulations
§ 1:15 —Methods of use
§ 1:16 —Method of manufacture or process claims
§ 1:17 —Product-by-process claims
§ 1:18 —Release profiles
§ 1:19 Conclusion

III. STATUTORY PROVISIONS

A. IN GENERAL

§ 1:20 Common statutory provisions of the patent law

B. SECTION 101: SUBJECT MATTER

§ 1:21 Patentable subject matter
C. SECTION 102: NOVELTY

§ 1:22 Novelty and "new" inventions
§ 1:23 Section 102(a)
§ 1:24 Section 102(b)
§ 1:25 —On-sale bar
§ 1:26 —Public use bar
§ 1:27 Section 102(c)
§ 1:28 Section 102(d)
§ 1:29 Section 102(e)—Utopian-world patent issuance in the USPTO
§ 1:30 —Understanding § 102(e) through example and timelines
§ 1:31 Section 102(f)—Inventor is not the inventor
§ 1:32 Section 102(g)—Prior invention by another
§ 1:33 —Contrasting section 102(g)(1) versus 102(g)(2)
§ 1:34 Conclusion

D. SECTION 103: OBVIOUSNESS

§ 1:35 Inventions more than trivial variations
§ 1:36 *Graham v. Deere* factors—Primary obviousness factors
§ 1:37 Timing of obviousness inquiry
§ 1:38 Guarding against hindsight—Motivation, suggestion, teaching (MST) to combine prior art
§ 1:39 —Combination of references—Flowing from the prior art
§ 1:40 —References—From nature of problem to be solved
§ 1:41 Secondary indicia of obviousness
§ 1:42 Unexpected results of the invention
§ 1:43 Long-felt need for the invention
§ 1:44 Failure of others to make the invention
§ 1:45 Copying by others—Benign factor in obviousness
§ 1:46 —Active ingredient
§ 1:47 —Formulation
§ 1:48 Licensing by others
§ 1:49 Commercial success—Generic drug infringement cases
§ 1:50 Skepticism by others and proof of nonobviousness
§ 1:51 Third-party praise and awards
§ 1:52 Chemical similarity—Chemical homology, isomerism, and structural similarity
§ 1:53 —Structural obviousness of chemical compounds
§ 1:54 —Isomers and obviousness
§ 1:55 Conclusion

xviii
E. SECTION 112: SPECIFICATION

§ 1:56 Role of the specification
§ 1:57 First paragraph
§ 1:58 —Written description
§ 1:59 —Enablement requirement
§ 1:60 —Best mode requirement
§ 1:61 —Conclusion
§ 1:62 Second paragraph: claim precision and boundaries
§ 1:63 Third and fourth paragraphs: dependent claims
§ 1:64 Conclusion

F. SECTIONS 119, 120 AND 121: PRIORITIES

§ 1:65 Priority and earliest filing dates
§ 1:66 Section 119: claiming foreign priority
§ 1:67 —Tool for evaluating prior art effect
§ 1:68 —Section 102(b) prior art is not affected by section 119(a)
§ 1:69 Claiming the benefit of earlier-filed applications
§ 1:70 Continuation applications for a different invention using the same specification
§ 1:71 Divisional applications for examiner-mandated restrictions to different inventions
§ 1:72 —Safe harbor provision of section 121 for divisional applications
§ 1:73 —Continuation-in-part applications—Introducing new matter

IV. PATENT TERM EXTENSION

§ 1:74 Patent term extension and patent expiration
§ 1:75 Embroilment in FDA—Sections 155, 155A, 156
§ 1:76 —Congressional patent term extensions
§ 1:77 —PTO delays
§ 1:78 —Uruguay round term extensions
§ 1:79 —Patent term restoration due to FDA approval processes
§ 1:80 ——Cap of five years
§ 1:81 Patent term restoration is a USPTO and FDA cooperation
§ 1:82 —Single and combination ingredients

V. ENANTIONERS

§ 1:83 History of enantiomer patentability
CHAPTER 2. PATENT INFRINGEMENT RULES AND PROCEDURES

I. INTRODUCTION
§ 2:1 Generally
§ 2:2 Basic infringement test

II. CLAIM CONSTRUCTION
§ 2:3 Generally

A. EVIDENCE
§ 2:4 Evidence considered in claim construction
§ 2:5 Intrinsic evidence must be considered first—Mandatory evidence
§ 2:6 Extrinsic evidence can be considered—Permissive evidence
§ 2:7 Dictionaries and treatises as sources of evidence of claim meaning

B. RULES
§ 2:8 Customary claim construction rules

C. NARROW CLAIM CONSTRUCTIONS
§ 2:9 Tools for the generic company
§ 2:10 Specification clearly defines claim term
§ 2:11 Claim term is implicitly defined by consistent use throughout specification
TABLE OF CONTENTS

§ 2:12 Pattern of examples in specification deduces claim meaning
§ 2:13 Embodiment is the invention
§ 2:14 Specification disavows particular meaning
§ 2:15 Specification explicitly disclaims definition
§ 2:16 Limiting the claim scope because consistent with invention's purpose
§ 2:17 Specification contains implicit disclaimer of definition
§ 2:18 Specifications and underclaiming—Claiming less than you could have
§ 2:19 Prosecution history as intrinsic evidence—Mandatory or permissive evidence
§ 2:20 Prosecution history contains narrow definition when ordinary meaning is unclear
§ 2:21 Claim term is narrowed because of disclaimer of ordinary meaning in prosecution history
§ 2:22 Using prosecution history of parent application in subsequent applications
§ 2:23 Choosing narrow claim scope when competing scopes exist

E. OTHER ISSUES

§ 2:24 Claim differentiation and interpreting claims of different scope
§ 2:25 Inexact modifiers or relative terminology
§ 2:26 Illustration regarding scope of “about”
§ 2:27 Timing of claim construction in view of issued patent

III. LITERAL INFRINGEMENT

§ 2:28 Generally
§ 2:29 Litigating more than one claim construction at trial: Federal Circuit review of record
§ 2:30 Special case: inherent infringement under single crystal theory
§ 2:31 Special case: Inherent infringement under single crystal theory—Impact of SmithKline v. Apotex on infringement
§ 2:32 Proving literal infringement
§ 2:33 Literal infringement as based on the generic drug application

IV. DOCTRINE OF EQUIVALENTS

§ 2:34 Doctrine of equivalents (DOE) infringement
§ 2:35 Tests for DOE
§ 2:36 —Insubstantial differences test for equivalency infringement
§ 2:37 —Function way result test
§ 2:38 —Element-by-element analysis
§ 2:39 Subject matter disclosed but not claimed “Dedication to the public” rule
§ 2:40 Doctrine of prosecution history estoppel (PHE)
§ 2:41 —Amendment-based estoppel
§ 2:42 ——Rebutting the presumption of estoppel
§ 2:43 ——Festo IX: Federal circuit summary of equivalency factors
§ 2:44 ——Festo Test Part 7: Rebutting prosecution history estoppel
§ 2:45 ——Festo Test Part 7(i): Foreseeable changes
§ 2:46 ——Foreseeability of drafting claim to equivalent: Is it new matter
§ 2:47 ——Festo Test Part 7(ii): Tangential relationship
§ 2:48 ——Festo Test Part 7(iii): Some other unexplained reason
§ 2:49 —Argument-based estoppel
§ 2:50 —Related applications may evoke estoppel
§ 2:51 —Scope
§ 2:52 —Prior art preclusions—Hypothetical claim analysis
§ 2:53 —Detailed structure test: An alternate to the insubstantial differences and function way result tests
§ 2:54 Case studies: SmithKline Beecham and Equivalency—Sustained release bupropion
§ 2:55 Case studies: SmithKline Beecham and Equivalency—Conclusion

V. INDIRECT INFRINGEMENT
§ 2:56 Contributory and inducement infringement generally
§ 2:58 ——Summary
§ 2:59 Contributory patent infringement under 35 U.S.C.A. § 271(c)
§ 2:60 —Knowing component is especially made
§ 2:61 —Substantial, noninfringing uses
§ 2:62 —Materiality
§ 2:63 Infringement under 35 U.S.C.A. § 271(g)—Importing drugs made by patented process
VI. CONCLUSION

§ 2:65 Generally

CHAPTER 3. FOUNDATIONS OF PATENT INVALIDITY

I. INTRODUCTION

§ 3:1 In general

II. PRIOR ART

§ 3:2 Burdens of proof—Prior art—Considered or not considered by examiner

§ 3:3 ——Sources

§ 3:4 ——Fully presented and vetted

§ 3:5 ——Cited but not vetted

§ 3:6 ——Not cited

III. ANTICIPATION

§ 3:7 Invalidating patent because invention is not new

§ 3:8 Element-by-element analysis, express and inherent anticipation

§ 3:9 Inherent anticipation

§ 3:10 ——Hypothetical

§ 3:11 ——SmithKline v. Apotex revisited

IV. OBVIOUSNESS

§ 3:12 Invalidity defense

§ 3:13 USPTO guidelines

§ 3:14 Combining prior art elements according to known methods to yield predictable results

§ 3:15 ——Simple substitution of one known element for another to obtain predictable results

§ 3:16 Known techniques to improve similar devices, methods, or products

§ 3:17 Applying known technique to yield predictable results

§ 3:18 “Obvious to try”—Choosing from finite number of items

§ 3:19 —Applicability to enantiomers, salt selection, and extended release (ER) formulations
§ 3:20 Market forces and design considerations
§ 3:21 Teaching, suggestion, or motivation in the prior art
§ 3:22 Person of ordinary skill in the art (POSITA)
§ 3:23 Structural obviousness—Breaking compound patents
§ 3:24 —Lansoprazole versus rabeprazole
§ 3:25 —Attacking of analogue of compound

V. “PRACTICING THE PRIOR ART”
§ 3:26 Defense to infringement

VI. GENUS AND SPECIES
§ 3:27 Interpretation
§ 3:28 Case study—Genus and species: Zyprexa®
(Olanzapine)
§ 3:29 —Enantiomers, invalidity, and Plavix® (clopidogrel)

VII. SECTION 112
§ 3:30 Patent invalidity theories
§ 3:31 Written description invalidity
§ 3:32 —Mechanics of written description challenge
§ 3:33 Enablement
§ 3:34 —Undue experimentation
§ 3:35 —“How to make”
§ 3:36 —“How to use”
§ 3:37 —In vitro to in vivo teaching
§ 3:38 —Effective amounts
§ 3:39 Best mode requirement
§ 3:40 Contrasting enablement and best mode
§ 3:41 Written description, enablement, and best mode—
Breaking chains of priority to invalidate later patents
§ 3:42 Rolling provisionals allow for chains of priority
§ 3:43 Section 112, second paragraph: claim precision and
boundaries
§ 3:44 Section 112, third and fourth paragraphs: dependent
claims

CHAPTER 4. INEQUITABLE CONDUCT AND PATENT UNENFORCEABILITY
§ 4:1 Inequitable conduct—Fraud on the Patent Office
§ 4:2 Types of inequitable conduct test—Common situations
§ 4:3 Penalties for inequitable conduct
| § 4:4 | Unenforceability—Later patents through infectious unenforceability |
| § 4:5 | Awarding attorney's fees and costs |
| § 4:6 | Fraud-based damages (Walker Process fraud) |
| § 4:7 | Private enforcement of fraud |
| § 4:8 | Curing inequitable conduct |
| § 4:9 | Asserting inequitable conduct—Not a game of gotcha |
| § 4:10 | Materiality threshold—Current and past tests for materiality |
| § 4:11 | Information does not have to be claimed |
| § 4:12 | Failure to comply with section 112(1) |
| § 4:13 | Information does not have to verbatim |
| § 4:14 | False statements |
| § 4:15 | Failure to disclose relationship of affiant to applicant |
| § 4:16 | Data is presumed material |
| § 4:17 | Failure to provide unfavourable test results |
| § 4:18 | Accurate description of test conditions |
| § 4:19 | Claim for priority |
| § 4:20 | Issues examiner focuses on |
| § 4:21 | Affirmative misrepresentations |
| § 4:22 | Intent to deceive |
| § 4:23 | Stressing importance of submitted prior art |
| § 4:24 | Gross negligence |
| § 4:25 | “Totality” can include gross negligence |
| § 4:26 | Mere denial is never enough to overcome inference of intent |
| § 4:27 | Searching for prior art |
| § 4:28 | Patterns of misrepresentations or omissions—Single actions |
| § 4:29 | Cultivated ignorance—Obtaining translations of foreign language documents |
| § 4:30 | “Burying” critical reference |
| § 4:31 | Failure to disclose prior art and foreign office actions from foreign searches |
| § 4:32 | False or misleading affidavits |
| § 4:33 | Failure to name proper inventors |
| § 4:34 | Pitfalls for patent applicants and corrective measures and practice tips |
| § 4:35 | Conclusion |

**CHAPTER 5. EQUITABLE DEFENSES TO PATENT INFRINGEMENT**

| § 5:1 | Introduction |
§ 5:2 Issue preclusion, collateral estoppel/claim preclusion and res judicata

§ 5:3 Laches—General principles

§ 5:4 —Quick comparison of laches and equitable estoppel

§ 5:5 —Factors

§ 5:6 —Laches and Presumptions

§ 5:7 Equitable estoppel—Factors

§ 5:8 —Presumptions

§ 5:9 —Prosecution laches

§ 5:10 —Recent developments

CHAPTER 6. BASICS OF BRAND DRUG APPROVAL PROCESS AND ORANGE BOOK LISTINGS

§ 6:1 Introduction

§ 6:2 Brand drug approval

§ 6:3 Investigational New Drug application (IND)—Beginning clinical trials

§ 6:4 —Contents

§ 6:5 New Drug Application (NDA)

§ 6:6 —Drug Master Files (DMF)

§ 6:7 Types of new drugs in NDA

§ 6:8 Internal FDA machinations

§ 6:9 Patent information and the Orange Book

§ 6:10 —Listable and nonlistable patents

§ 6:11 —Patent listing as clerical not substantive

§ 6:12 —Delisting patents

§ 6:13 —Forcible listing of unlisted patents

§ 6:14 When patents may be listed

§ 6:15 Who may list which patents

§ 6:16 Medical device patents and antibiotic patents—Status

§ 6:17 Polymorph patent listing

§ 6:18 Blinds and clinical testing

§ 6:19 —Clinical trial phases

§ 6:20 ——Public use patent invalidity

§ 6:21 “Paper NDAs”—New Drug Applications/section 505(b)(2) applications

§ 6:22 NDA approval and approval dates

CHAPTER 7. ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVAL PROCESS

§ 7:1 Reference Listed Drug (RLD)
<table>
<thead>
<tr>
<th>Section</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>§ 7:2</td>
<td>Suitability petitions to refer to different RLDs</td>
</tr>
<tr>
<td>§ 7:3</td>
<td>Abbreviated New Drug Application (ANDA)</td>
</tr>
<tr>
<td>§ 7:4</td>
<td>—Differences between the NDA and ANDA</td>
</tr>
<tr>
<td>§ 7:5</td>
<td>—Bioequivalency of generic drug</td>
</tr>
<tr>
<td>§ 7:6</td>
<td>Inner workings of the FDA</td>
</tr>
<tr>
<td>§ 7:7</td>
<td>Labeling review</td>
</tr>
<tr>
<td>§ 7:8</td>
<td>Chemistry and manufacturing controls (CMC)</td>
</tr>
<tr>
<td>§ 7:9</td>
<td>Biopharmaceutical review and bioavailability</td>
</tr>
<tr>
<td>§ 7:10</td>
<td>Classification system for biopharmaceutical properties</td>
</tr>
<tr>
<td>§ 7:11</td>
<td>—Patents claiming pharmacokinetics</td>
</tr>
<tr>
<td>§ 7:12</td>
<td>Microbiology review</td>
</tr>
<tr>
<td>§ 7:13</td>
<td>Clinical review</td>
</tr>
<tr>
<td>§ 7:14</td>
<td>cGMP review</td>
</tr>
<tr>
<td>§ 7:15</td>
<td>Deficiency Letters</td>
</tr>
<tr>
<td>§ 7:16</td>
<td>—Major Deficiency Letter</td>
</tr>
<tr>
<td>§ 7:17</td>
<td>—Minor Deficiency Letter</td>
</tr>
<tr>
<td>§ 7:18</td>
<td>——Telephone Amendment</td>
</tr>
<tr>
<td>§ 7:19</td>
<td>Approval matrix</td>
</tr>
<tr>
<td>§ 7:20</td>
<td>Final approval versus tentative approval</td>
</tr>
<tr>
<td>§ 7:21</td>
<td>Tentative approval—Reasons for getting it</td>
</tr>
<tr>
<td>§ 7:22</td>
<td>Patent attorney involvement in answering deficiency letters</td>
</tr>
<tr>
<td>§ 7:23</td>
<td>Showing bioequivalency of generic versions</td>
</tr>
<tr>
<td>§ 7:24</td>
<td>Bioavailability defined</td>
</tr>
<tr>
<td>§ 7:25</td>
<td>Bioequivalency defined</td>
</tr>
<tr>
<td>§ 7:26</td>
<td>Measuring bioequivalence of traditional solid oral dosage forms—Immediate and extended release forms</td>
</tr>
<tr>
<td>§ 7:27</td>
<td>—Extended release (ER) forms</td>
</tr>
<tr>
<td>§ 7:28</td>
<td>Extended release types—Diffusion control system</td>
</tr>
<tr>
<td>§ 7:29</td>
<td>—Dissolution control system</td>
</tr>
<tr>
<td>§ 7:30</td>
<td>—Erosion control system</td>
</tr>
<tr>
<td>§ 7:31</td>
<td>—Osmotic pump system</td>
</tr>
<tr>
<td>§ 7:32</td>
<td>—Ion-exchange resin system</td>
</tr>
<tr>
<td>§ 7:33</td>
<td>Proving bioequivalency</td>
</tr>
<tr>
<td>§ 7:34</td>
<td>—In vitro dissolution studies</td>
</tr>
<tr>
<td>§ 7:35</td>
<td>—Dissolution testing and standardized testing protocols</td>
</tr>
<tr>
<td>§ 7:36</td>
<td>—Particle size and dissolution testing</td>
</tr>
<tr>
<td>§ 7:37</td>
<td>In vitro bioequivalency (BE) testing—Reasons for BE testing and biowaivers</td>
</tr>
<tr>
<td>§ 7:38</td>
<td>Biostudies in human subjects—Pilot and pivotal biostudies</td>
</tr>
<tr>
<td>§ 7:39</td>
<td>—Fasting and fed biostudies</td>
</tr>
</tbody>
</table>
§ 7:40 ——Food effect patents are not patentable
§ 7:41 Impurity specifications
§ 7:42 Impurity levels as defined by a regulatory authority
§ 7:43 Avoiding impurity patent claims may jeopardize regulatory approval
§ 7:44 Metered and powder dose inhalers
§ 7:45 Dry powder dose inhalers (DPI)
§ 7:46 Nasal sprays and inhaled solutions, sprays
§ 7:47 Samples and patent issues in samples
§ 7:48 Changes to the Abbreviated New Drug Application
§ 7:49 ——Major changes
§ 7:50 ——Moderate changes—Changes being effected in 30 days (CBE-30)
§ 7:51 ——Minor change—Minimal impact change documented in annual report
§ 7:52 Changes to the ANDA and patent issues
§ 7:53 Review of ANDA approval process

CHAPTER 8. "PAPER NDA" AND SECTION 505(B)(2) APPLICATIONS
§ 8:1 Section 505(b)(2) application—General principles
§ 8:2 Contrasting 505(b)(2) applications with Abbreviated New Drug Applications (ANDA)
§ 8:3 Similarities between 505(b)(2) application and ANDA
§ 8:4 General types of applications
§ 8:5 Information needed to support the application
§ 8:6 Strategic uses
§ 8:7 —Use of a 505(b)(2) application to circumvent the 180-day exclusivity
§ 8:8 Conclusion

CHAPTER 9. PATENT INFRINGEMENT SAFE HARBOR EXEMPTIONS
§ 9:1 Introduction
§ 9:2 Genesis of safe harbor exemption—Roche v. Bolar
§ 9:3 Hatch Waxman Act/Safe harbor exemption—Scope of exemption
§ 9:4 “Information” development and “information” submission to FDA
§ 9:5 Reasonable scope of exemption
§ 9:6 —Medical devices and other ostensibly unrelated activities
CHAPTER 10. MECHANICS OF ORANGE BOOK PATENT CERTIFICATIONS AND NOTICE LETTERS

§ 10:1 Introduction
§ 10:2 Patent certifications and Orange Book listing
§ 10:3 —Paragraph I, II, III, or IV certifications
§ 10:4 —Impact on ANDA approval
§ 10:5 —Hypothetical patent certifications—Case study on Viagra
§ 10:6 Section (viii) statements—Carving out patented methods of use
§ 10:7 —Working example on Section viii Statements—Sertraline
§ 10:8 —One and only indication
§ 10:9 —Carving out indications to unlisted patents
§ 10:10 —Request Listing
§ 10:11 —Using Suitability Petitions to allow carve out
§ 10:12 Combining Paragraph I certification in lieu of Section viii Statement
§ 10:13 —Paragraph IV certification and Notice Letter requirements
§ 10:14 —Identifying the patents in the Notice Letter
§ 10:15 —Content and sufficiency of the Notice Letter
§ 10:16 —How much detail is necessary
§ 10:17 —Details on claims that are not normally listable
§ 10:18 —Form of Letter and Detailed Statement
§ 10:19 —Admonishments—Appending Letter to a complaint
§ 10:20 — —Predicates to antitrust injury
§ 10:21 How to send the Notice Letter
§ 10:22 Where to send the Notice Letter
§ 10:23 When to send the Notice Letter
§ 10:24 Updating the FDA on Notice Letters
Chapter 11. The 30-Month Injunction/Stay

I. Generally

§ 11:1 Introduction
§ 11:2 Creating the 30-month stay and counting days
§ 11:3 Who notifies the FDA of the lawsuit

II. Termination of the 30-Month Stay

§ 11:4 How the 30-month stay is normally terminated
§ 11:5 Court decision
§ 11:6 Generic company wins
§ 11:7 Generic company wins on appeal
§ 11:8 Patentee delays

III. Lengthening, Shortening, or Reinstating the Stay

§ 11:9 Extending stay because court made no decision
§ 11:10 Reinstating if wrongfully terminated
§ 11:11 Lengthening or shortening due to lack of cooperation
§ 11:12 Cases extending the 30-month stay
§ 11:13 Cases shortening the 30-month stay
§ 11:14 Cases where the stay was not altered despite request to alter

IV. Effect of Delays

§ 11:15 Blowing the 45-day window—Can suit still be brought?

V. Earning New 30-Month Stays

§ 11:16 Generally
TABLE OF CONTENTS

§ 11:17 Repetitive 30-month stays under the old rules
§ 11:18 Earning 30-month stays under the December 2003 rules
§ 11:19 Effect of pop-up (newly issued) patents
§ 11:20 Working examples of the 30-month stay

VI. STAGGERED EXPIRATIONS

§ 11:21 Multiple applicants 30-month stay; staggered stay expiries

CHAPTER 12. BRAND SIDE EXCLUSIVITIES

§ 12:1 Filing and approval exclusivities
§ 12:2 New Chemical Entity (NCE) exclusivity [five-year]
§ 12:3 —When to file ANDAs with Paragraph IV certifications
§ 12:4 —Extensions of the 30-month stay
§ 12:5 —Delisting patents from Orange Book right before NCE-1 date
§ 12:6 New product/clinical information/supplemental exclusivity [three-year]
§ 12:7 —Requirements for the new clinical information exclusivity
§ 12:8 —Requirements—Working example for generic approval of less than all indications
§ 12:9 —Difference between NCE and three-year exclusivity
§ 12:10 Three-year exclusivity for enantiomers
§ 12:11 Orphan drug exclusivity [seven-year exclusivity]
§ 12:12 Pediatric exclusivity [six months]
§ 12:13 —Effect
§ 12:14 —Tracking
§ 12:15 —Effect on ANDA filings
§ 12:16 —Effect on the 30-month stay
§ 12:17 ——Working examples of pediatric exclusivity
§ 12:18 ——Working examples—Ranbaxy v. FDA and Pfizer; fluconazole
§ 12:19 ———Alza v. Mylan/Mylan v. FDA; fentanyl patch
§ 12:20 ——Effects on the 30-month stay—Working examples—Pfizer v. Apotex; amlodipine
§ 12:21 —Pediatric exclusivity and combination products
§ 12:22 Patent infringement implications
§ 12:23 Key points about pediatric exclusivity
CHAPTER 13. THE 180-DAY EXCLUSIVITY

§ 13:1 Introduction
§ 13:2 Creating the 180-day exclusivity
§ 13:3 Against whom the 180-day exclusivity applies
§ 13:4 FDA's product-by-product approach to patent certifications
§ 13:5 Product-by-product approach to exclusivity
§ 13:6 180-day exclusivity naturally expires with the underlying patent
§ 13:7 Triggering the 180-day exclusivity clock
§ 13:8 —Under pre-December 2003 MMA rules
§ 13:9 —Under the post-MMA rules
§ 13:10 Tracking the 180-day exclusivity
§ 13:11 Reissue patents and new 180-day exclusivities
§ 13:12 Authorized generics
§ 13:13 —Curbing by Medicaid Best Price Law
§ 13:14 Waiver or relinquishment of the 180-day exclusivity
§ 13:15 —Mechanics of selective waiver and total relinquishment

CHAPTER 14. FORFEITURE OF THE 180-DAY EXCLUSIVITY

§ 14:1 Introduction
§ 14:2 Forfeiture provisions
§ 14:3 —Failure to market
§ 14:4 —No litigation pending; 30 months to approval, 75 days to market
§ 14:5 —Litigation pending
§ 14:6 —Rationalizing the failure to market provisions; no patent litigation
§ 14:7 Contrived patent litigation, possibility of suit to avoid forfeits
§ 14:8 Settling lawsuits but maintaining the Paragraph IV to avoid forfeits
§ 14:9 Withdrawal of application
§ 14:10 Amendment of certification
§ 14:11 Failure to obtain tentative approval
§ 14:12 —Tentative approval, changed conditions, and citizen petitions
§ 14:13 Agreements that violate antitrust laws
§ 14:14 Expiration of patents
Table of Contents

§ 14:15 No-rolling exclusivity
§ 14:16 Forfeitures in general policy terms

CHAPTER 15. DECLARATORY JUDGMENT

§ 15:1 Introduction: purpose of the Declaratory Judgment Act (DJA)
§ 15:2 When DJs are used in pharmaceutical patent cases
§ 15:3 Traditional declaratory judgment standards
§ 15:4 Post-MedImmune declaratory judgment standards
§ 15:5 —Famciclovir case and factors allowing a declaratory judgment action
§ 15:6 Declaratory judgments to trigger exclusivity
§ 15:7 —Orange Book listing alone could confer DJ jurisdiction
§ 15:8 ——Patents listed but statutorily disclaimed do not confer jurisdiction
§ 15:9 Covenants not to sue; removing fear of suit
§ 15:10 ——Covenants divesting court’s jurisdiction

CHAPTER 16. PATENT INFRINGEMENT DAMAGES AND REMEDIES

§ 16:1 Introduction
§ 16:2 Potential remedies for patent infringement
§ 16:3 Impact of the loss on the ANDA approval status and redating the ANDA approval date
§ 16:4 ——ANDAs for old antibiotics should not have redated approval dates
§ 16:5 Injunctive relief to stop future infringement or prevent at-risk launch
§ 16:6 ——Other factors to consider in whether to grant a launch-prevention injunction
§ 16:7 Awarding an injunction against future infringement when generic company loses
§ 16:8 Product recall of generic products in the marketplace
§ 16:9 Money damages for patent infringement
§ 16:10 —Money damages, reasonable royalty or lost profits
§ 16:11 ——Reasonable royalty
§ 16:12 ——Hypothetical negotiations
§ 16:13 ——Factors to consider in setting the royalty: Georgia Pacific test
§ 16:14 — — factors in relation to generic drug infringement
§ 16:15 — Effect on permanent injunction
§ 16:16 — Lost profits
§ 16:17 — Lost profits and market reconstruction
§ 16:18 — — No lost profits when substitutes exist
§ 16:19 — — No lost profits when substitutes and authorized generics exist
§ 16:20 — Calculating lost profits and bringing expenses into the calculus
§ 16:21 — Expense deductions
§ 16:22 Enhanced damages and willful infringement
§ 16:23 — Willful infringement and factors to consider
§ 16:24 — Legal opinions and willful infringement
§ 16:25 — Willful infringement for filing an ANDA
§ 16:26 — Willfulness and the need to specify facts in the pleading
§ 16:27 Exceptional cases and attorney fees
§ 16:28 — When can attorney fees be awarded
§ 16:29 — Steps in awarding attorney fees
§ 16:30 — Who is a prevailing party
§ 16:31 — Attorney fee amounts
§ 16:32 — Case study: Pioglitazone and attorney fee awarded to patentee

Table of Cases

Index